The U.K. is under pressure to offer a better deal to global pharmaceutical firms, as a slew of pulled investments and stalled drug pricing talks loom over U.S. President Donald Trump's state visit to Britain. Drug companies have been urging U.K. authorities to pay more for drugs and improve the competitive landscape ahead of a fast-approaching deadline later this month under Trump's most favored nation (MFN) drug pricing order. But with little movement from the government so far, firms have been pulling the plug on proposed investments in Britain, in what some analysts suggest could be a negotiating tactic to boost U.K. support. "We think that this is, at this point, a negotiating tactic and many of these companies will not walk away completely and will kind of redesign their investments,"

See Full Page